Mostrando 7 resultados de: 7
Filtros aplicados
Subtipo de publicación
Article(7)
Publisher
Bionatura(2)
Cancer Biology and Therapy(1)
Drugs of the Future(1)
European Journal of Pharmaceutical Sciences(1)
Hybridoma(1)
Objetivos de Desarrollo Sostenible
ODS 10: Reducción de las desigualdades(7)
ODS 3: Salud y bienestar(7)
ODS 17: Alianzas para lograr los objetivos(5)
ODS 5: Igualdad de género(1)
ODS 9: Industria, innovación e infraestructura(1)
Origen
scopus(7)
A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer
ArticleAbstract: Nimotuzumab is a humanized IgG1 monoclonal antibody against the EGFR extracellular domain that has bPalabras claves:Advanced cervical cancer, eGFR, Monoclonal antibody, nimotuzumab, Pilot studyAutores:Astudillo H., Avila S., Bazán B., Bojalil R., Cetina L., Charco E., Coronel J., Dueñas-Gonzãlez A., Jiménez-Lima R., Ramos M., Tania Crombet, Zapata S.Fuentes:scopusEvaluation of CIMAvaxEGF for the treatment of lung cancer: Meta-analysis of controlled clinical trials
ArticleAbstract: CIMAvaxEGF is a therapeutic cancer vaccine developed in Cuba and fully licensed in the country for uPalabras claves:EGF receptor, Epidermal growth factor, immunotherapy, Of non-small cell lung cancer vaccine therapy, Oncology vaccinesAutores:Aliuska Frías, Ballesteros J., Bárbara Wilkinson, Camilo Rodríguez, Carmen Elena Viada, Mabel Álvarez, Martha M. Fors-López, Neninger Vinageras E., Quintero J., Robaina M., Tania CrombetFuentes:scopusIntegrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody
ArticleAbstract: The multiple-dose strategy with the monoclonal ior EGF/r3 antibody, in xenograft bearing nude mice,Palabras claves:Allometric scaling, Dosage regimen, Integrated pharmacokinetic-pharmacodynamic, Monoclonal antibody ior EGF/r3, Survival time, Tumor growth delayAutores:Alonso K., Alvarez D., Beausoleil I., Bécquer M.d.l.A., Castillo R., Duconge J., Fernández-Sánchez E.M., Matheu J., Tania Crombet, Valenzuela-Silva C.M., Vecino G.Fuentes:scopusPharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer
ArticleAbstract: Epidermal growth factor receptor (EGFR) overexpression has been detected in many tumors of epitheliaPalabras claves:Epidermal growth factor receptor, Monoclonal antibody, Phase I clinical trialAutores:Catala M., Iznaga N., Lage Davila A., Neninger Vinageras E., Perera A., Pérez R., Solano M., Tania Crombet, Torres F., Torres L., Torres O.Fuentes:scopusNimotuzumab for the treatment of patients with malignant glioma. Comparison between pre-registration and post-approved studies
ArticleAbstract: Nimotuzumab is a monoclonal antibody targeted against the epidermal growth factor receptor approvedPalabras claves:And High-grade glioma, Controlled clinical studies, nimotuzumab, Postmarking studies, Target therapiesAutores:Aliuska Frías, Carmen Elena Viada, García L., Luaces P.L.o., Mabel Álvarez, Macías A.E., Santiesteban Y., Saurez G., Tania CrombetFuentes:scopusShort communication: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: Preliminary study
ArticleAbstract: High levels of growth factors and their receptors have been demonstrated in human tumors. Gliomas anPalabras claves:Autores:Figueredo R., Iznaga N., Lage Davila A., Menéndez A., Pérez R., Ramos M., Rodríguez V., Stevenson A., Tania Crombet, Torres F., Torres O., Veitía I.Fuentes:scopush-R3: Treatment of Head and Neck Cancer Treatment of Epithelial Tumors Anti-EGFR MAb
ArticleAbstract: Epidermal growth factor receptor (EGFR) overexpression has been associated with alterations in cellPalabras claves:Autores:Iznaga-Escobar N., Parada A.C., Tania CrombetFuentes:scopus